

FILE 'HOME' ENTERED AT 02:21:35 ON 20 JUN 2008

=> file reg  
COST IN U.S. DOLLARS  
SINCE FILE ENTRY TOTAL  
SESSION  
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 02:22:24 ON 20 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 JUN 2008 HIGHEST RN 1029146-45-9  
DICTIONARY FILE UPDATES: 18 JUN 2008 HIGHEST RN 1029146-45-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> E  
 " (R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROPROPOXY)BENZYL)AMINO)-2,2,2-TRIFLUOROETHANOL"/CN 25  
 E1 1 (R)-1-((4,4'-DIMETHOXYTRITYL)OXY)-2-PROPANOL/CN  
 E2 1  
 (R)-1-((4-((5-METHYL-2-(4-TRIFLUOROMETHYLPHENYL)OXAZOL-4-YL)METHOXY)BENZENE)SULFONYL)  
 )-2,3-DIHYDRO-1H-INDOLE-2-CARBOXYLIC ACID/CN  
 E3 0 -->  
 (R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROPROPOXY)BENZYL)AMINO)-2,2,2-TRIFLUOROETHANOL/CN  
 E4 1  
 (R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID  
 (2,2-DIMETHYLPROPYL)AMIDE/CN  
 E5 1  
 (R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID  
 ISOPROPYLAMIDE/CN  
 E6 1  
 (R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID  
 TERT-BUTYLAMIDE/CN  
 E7 1 (R)-1-((4-AZIDO-3,4-DIHYDRO-2H-CHROMEN-7-YL)METHYL)PIPERIDINE/CN  
 E8 1 (R)-1-((4-AZIDOCROMAN-7-YL)METHYL)-4-FLUOROPIPERIDINE/CN  
 E9 1 (R)-1-((4-CHLOROPHENYL)SULFONYL)-2-PROPANOL/CN  
 E10 1  
 (R)-1-((4-METHYL-3-((((4-NITROBENZYL)OXY)CARBONYL)METHYL)PHENYL)SULFONYL)-4-(5-TRIFLUOROMETHYLPYRIDIN-2-YL)PIPERAZINE-2-CARBOXYLIC ACID METHYL ESTER/CN  
 E11 1 (R)-1-((4-TOLYL)SULFONYL)-2-PROPANOL/CN  
 E12 1 (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC  
 ACID (2,2-DIMETHYLPROPYL)AMIDE/CN  
 E13 1 (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC  
 ACID ISOPROPYLAMIDE/CN

E14 1 (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC  
 ACID TERT-BUTYL ESTER/CN  
 E15 1 (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC  
 ACID TERT-BUTYLAamide/CN  
 E16 1  
 (R)-1-((5,6-DIMETHOXYBIPHENYL-3-YL)CARBONYL)AZETIDINE-2-CARBOXYLIC ACID  
 HYDROXYAMIDE/CN  
 E17 1  
 (R)-1-((5,6-DIMETHOXYBIPHENYL-3-YL)CARBONYL)AZETIDINE-2-CARBOXYLIC ACID METHYL  
 ESTER/CN  
 E18 1  
 (R)-1-((5-(5-CHLOROTHIEN-2-YL)ISOXAZOL-3-YL)METHYL)-1H-INDOLE-2-CARBOXYLIC ACID  
 N-(1-ETHYL PYRROLIDIN-3-YL)AMIDE/CN  
 E19 1  
 (R)-1-((5-(5-CHLOROTHIEN-2-YL)ISOXAZOL-3-YL)METHYL)-1H-INDOLE-2-CARBOXYLIC ACID  
 N-(1-ISOPROPYL PYRROLIDIN-3-YL)AMIDE/CN  
 E20 1  
 (R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)-4-FLUOROPIPERIDINE/CN  
 E21 1  
 (R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)-4-METHYLPIPERAZINE/CN  
 E22 1  
 (R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)PIPERIDINE/CN  
 E23 1  
 (R)-1-((5-PHENYLTHIENO(3,2-B)PYRIDIN-7-YL)CARBONYL)-2-HYDROXYMETHYL PYRROLIDINE/CN  
 E24 1  
 (R)-1-((6-((3-FLUOROPHENYL)SULFONYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHYL)-1-METHYLUREA/CN  
 E25 1  
 (R)-1-((6-BROMO-2-PHENYL-4-QUINOLINYL)CARBONYL)-2-HYDROXYMETHYL PYRROLIDINE/CN  
  
 => E  
 "(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROETHOXY)BENZYL)AMINO)-2,2,2-TRIFLUOROETHANOL"/CN 25  
 E1 1 (R)-1-((4,4'-DIMETHOXYTRITYL)OXY)-2-PROPANOL/CN  
 E2 1  
 (R)-1-((4-((5-METHYL-2-(4-TRIFLUOROMETHYLPHENYL)OXAZOL-4-YL)METHOXY)BENZENE)SULFONYL)-2,3-DIHYDRO-1H-INDOLE-2-CARBOXYLIC ACID/CN  
 E3 0 -->  
 (R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROETHOXY)BENZYL)AMINO)-2,2,2-TRIFLUOROETHANOL/CN  
 E4 1  
 (R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID  
 (2,2-DIMETHYLPROPYL)AMIDE/CN  
 E5 1  
 (R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID  
 ISOPROPYLAMIDE/CN  
 E6 1  
 (R)-1-((4-(DIFLUOROMETHYL)PHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC ACID  
 TERT-BUTYLAamide/CN  
 E7 1 (R)-1-((4-AZIDO-3,4-DIHYDRO-2H-CHROMEN-7-YL)METHYL)PIPERIDINE/CN  
 E8 1 (R)-1-((4-AZIDOCROMAN-7-YL)METHYL)-4-FLUOROPIPERIDINE/CN  
 E9 1 (R)-1-((4-CHLOROPHENYL)SULFONYL)-2-PROPANOL/CN  
 E10 1  
 (R)-1-((4-METHYL-3-(((4-NITROBENZYL)OXY)CARBONYL)METHYL)PHENYL)SULFONYL)-4-(5-TRIFLUOROMETHYL PYRIDIN-2-YL)PIPERAZINE-2-CARBOXYLIC ACID METHYL ESTER/CN  
 E11 1 (R)-1-((4-TOLYL)SULFONYL)-2-PROPANOL/CN  
 E12 1 (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC  
 ACID (2,2-DIMETHYLPROPYL)AMIDE/CN  
 E13 1 (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC  
 ACID ISOPROPYLAMIDE/CN  
 E14 1 (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC  
 ACID TERT-BUTYL ESTER/CN

E15 1 (R)-1-((4-TRIFLUOROMETHYLPHENYL)SULFONYL)PIPERIDINE-2-CARBOXYLIC  
 ACID TERT-BUTYLAMIDE/CN  
 E16 1 (R)-1-((5,6-DIMETHOXYBIPHENYL-3-YL)CARBONYL)AZETIDINE-2-CARBOXYLIC ACID  
 HYDROXYAMIDE/CN  
 E17 1 (R)-1-((5,6-DIMETHOXYBIPHENYL-3-YL)CARBONYL)AZETIDINE-2-CARBOXYLIC ACID METHYL  
 ESTER/CN  
 E18 1 (R)-1-((5-(5-CHLOROTHIEN-2-YL)ISOXAZOL-3-YL)METHYL)-1H-INDOLE-2-CARBOXYLIC ACID  
 N-(1-ETHYLPYRROLIDIN-3-YL)AMIDE/CN  
 E19 1 (R)-1-((5-(5-CHLOROTHIEN-2-YL)ISOXAZOL-3-YL)METHYL)-1H-INDOLE-2-CARBOXYLIC ACID  
 N-(1-ISOPROPYLPYRROLIDIN-3-YL)AMIDE/CN  
 E20 1 (R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)-4-FLUOROPIPERIDINE/CN  
 E21 1 (R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)-4-METHYLPIPERAZINE/CN  
 E22 1 (R)-1-((5-AZIDO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)METHYL)PIPERIDINE/CN  
 E23 1 (R)-1-((5-PHENYLTHIENO(3,2-B)PYRIDIN-7-YL)CARBONYL)-2-HYDROXYMETHYL PYRROLIDINE/CN  
 E24 1 (R)-1-((6-((3-FLUOROPHENYL)SULFONYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHYL)-1-METHYLUREA/CN  
 E25 1 (R)-1-((6-BROMO-2-PHENYL-4-QUINOLINYL)CARBONYL)-2-HYDROXYMETHYL PYRROLIDINE/CN  
  
 => E  
 "(R)-3-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROETHOXY)BENZYL)AMINO)-1,1,1-TRIFLUOROPROPAN-2-OL"/CN 25  
 E1 1 (R)-3-((4-(4,4,4-TRIFLUORO-1-(4-(5-TRIFLUOROMETHYL PYRIDIN-2-YL)PHENYL)BUTOXY)BENZOYL)AMINO)PROPIONIC ACID METHYL ESTER/CN  
 E2 1 (R)-3-((4-(4-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-2-(4-CYCLOHEXYLPHENYL)-4-OXOBUTYRYL)BENZOYL)AMINO)PROPIONIC ACID/CN  
 E3 0 --> (R)-3-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAFLUOROETHOXY)BENZYL)AMINO)-1,1,1-TRIFLUOROPROPAN-2-OL/CN  
 E4 1 (R)-3-((4-(MORPHOLINO)-1,2,5-THIADIAZOL-3-YL)OXY)-1,2-PROPANEDIOL/CN  
 E5 1 (R)-3-((4-(TRIFLUOROMETHYL)PHENYL)AMINO)PENTANAMIDE/CN  
 E6 1 (R)-3-((4-(TRIFLUOROMETHYL)PHENYL)AMINO)PENTANOIC ACID/CN  
 E7 1 (R)-3-((4-(TRIFLUOROMETHYL)PHENYL)AMINO)PENTANOIC ACID ETHYL  
 ESTER/CN  
 E8 1 (R)-3-((4-(TRIFLUOROMETHYL)PHENYL)AMINO)PENTANOIC ACID METHYL  
 ESTER/CN  
 E9 1 (R)-3-((4-BENZYLPIPERAZIN-1-YL)METHYL)PIPERIDINE-1-CARBOXYLIC  
 ACID TERT-BUTYL ESTER/CN  
 E10 1 (R)-3-((4-BROMOPHENYL)((4-TOLYL)SULFONYL)AMINO)METHYL)-1H-INDOLE/CN  
 E11 1 (R)-3-((4-BROMOPHENYL)(2-TRIFLUOROMETHYLPHENYL)METHOXY)-N-TERT-BUTYL AZETIDINE-1-CARB  
 OXAMIDE/CN  
 E12 1 (R)-3-((4-BROMOPHENYL)(2-TRIFLUOROMETHYLPHENYL)METHOXY)AZETIDINE/CN  
 E13 1 (R)-3-((4-CHLOROPHENYL)(2-TRIFLUOROMETHYLPHENYL)METHOXY)AZETIDINE/CN  
 E14 1 (R)-3-((4-CHLOROPHENYL)CARBAMOYL)-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID  
 TERT-BUTYL ESTER/CN

E15 1 (R)-3-((4-CYANOBENZYL)OXY)-1H-PYRROLIDINE/CN  
 E16 1 (R)-3-((4-ETHOXYSUBZOYL)AMINO)-2-(((1-PHENYL-3-TRIFLUOROMETHYL-1H-PYRAZOL-4-YL)CARBO  
NYL)AMINO)PROPANOIC ACID/CN  
 E17 1 (R)-3-((4-ETHOXYSUBZOYL)AMINO)-2-(((1-PHENYL-3-TRIFLUOROMETHYL-1H-PYRAZOL-4-YL)CARBO  
NYL)AMINO)PROPANOIC ACID METHYL ESTER/CN  
 E18 1 (R)-3-((4-FLUORO-3-TRIFLUOROMETHYLBENZOYL)AMINO)PYRROLIDINE-1-CARBOXYLIC ACID  
N-(7-METHOXYSUBIAZOLO(5,4-D)PYRIMIDIN-2-YL)AMIDE/CN  
 E19 1 (R)-3-((4-FLUORO-3-TRIFLUOROMETHYLBENZOYL)AMINO)PYRROLIDINE-1-CARBOXYLIC ACID  
N-(7-METHOXYSUBIAZOLO(5,4-D)PYRIMIDIN-2-YL)AMIDE/CN  
 E20 1 (R)-3-((4-METHOXYSUBZYL)OXY)-2-BUTANONE/CN  
 E21 1 (R)-3-((4-METHOXYSUBZYL)OXY)OCT-1-ENE/CN  
 E22 1 (R)-3-((4-METHYLSULFONYL-2-(PIPERIDIN-3-YLMETHOXY)BENZOYL)AMINO)-N-(5-CHLOROPYRIDIN-  
2-YL)PYRIDINE-2-CARBOXAMIDE/CN  
 E23 1 (R)-3-((4-TOLYL)((4-TOLYL)SULFONYL)AMINO)METHYL-1H-INDOLE/CN  
 E24 1 (R)-3-((5-((AZETIDIN-1-YL)CARBONYL)PYRAZIN-2-YL)OXY)-5-((1-METHYL-2-OXOPYRROLIDIN-3-  
YL)OXY)-N-(4-METHYL-1,3-SUBIAZOLO-2-YL)BENZAMIDE/CN  
 E25 1 (R)-3-((5-((AZETIDIN-1-YL)CARBONYL)PYRAZIN-2-YL)OXY)-5-((1-METHYL-2-OXOPYRROLIDIN-3-  
YL)OXY)BENZOIC ACID/CN

=>


Uploading C:\Program Files\STNEXP\Queries\10\_678145 CETPI Structure.str

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1 SSS SAM

SAMPLE SEARCH INITIATED 02:33:31 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 34 TO ITERATE

100.0% PROCESSED 34 ITERATIONS  
SEARCH TIME: 00.00.01

3 ANSWERS


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 331 TO 1029  
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> d scan L2

L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 2-Propanol, 3-[3-[3-(1,1-dimethylethyl)phenoxy]phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-, (2R)-  
MF C28 H28 F7 N O3

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2


L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 2-Propanol, 3-[3-(3-ethyl-5-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-, (2R)-  
MF C27 H26 F7 N O3

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 3 ANSWERS  REGISTRY COPYRIGHT 2008 ACS on STN  
 IN 2-Propanol, 3-[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-  
 MF C26 H23 Cl F7 N O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=>  
 Uploading C:\Program Files\STNEXP\Queries\10\_678145 CETPI Structure2.str

L3           STRUCTURE UPLOADED

=> d L3  
 L3 HAS NO ANSWERS  
 L3           STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s L3 SSS SAM
SAMPLE SEARCH INITIATED 02:36:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      34 TO ITERATE


100.0% PROCESSED      34 ITERATIONS          2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS:      331 TO      1029
PROJECTED ANSWERS:          2 TO       124
```

L4 2 SEA SSS SAM L3

=> d L4 1-2

```
L4  ANSWER 1 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN  263342-63-8 REGISTRY
ED  Entered STN: 28 Apr 2000
CN  2-Propanol, 3-[3-(4-chloro-3-ethylphenoxy)phenyl][3-(1,1,2,2-
     tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro- (CA INDEX NAME)
MF  C26 H23 Cl F7 N O3
SR  CA
LC  STN Files: CA, CAPLUS, CASREACT, USPAT2, USPATFULL
```




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

9 REFERENCES IN FILE CA (1907 TO DATE)  
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 263264-49-9 REGISTRY  
ED Entered STN: 27 Apr 2000  
CN 2-Propanol, 3-[[3-(3-ethyl-5-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-, (2R)- (CA INDEX NAME)  
FS STEREOSEARCH  
MF C27 H26 F7 N O3  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s L3 SSS Full  
FULL SEARCH INITIATED 02:36:20 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 698 TO ITERATE

100.0% PROCESSED 698 ITERATIONS  
SEARCH TIME: 00.00.01


6 ANSWERS

L5 6 SEA SSS FUL L3

=> d scan L5

L5 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 2-Propanol, 3-[3-(3-ethyl-5-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-, (2R)-  
MF C27 H26 F7 N O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L5 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 2-Propanol, 3-[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-  
MF C26 H23 Cl F7 N O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L5 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 2-Propanol, 3-[3-(3-ethyl-5-methylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro-  
MF C27 H26 F7 N O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

(FILE 'HOME' ENTERED AT 02:21:35 ON 20 JUN 2008)

FILE 'REGISTRY' ENTERED AT 02:22:24 ON 20 JUN 2008

E "(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF  
E "(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF  
E "(R)-3-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF

L1           STRUCTURE uploaded  
L2        3 S L1 SSS SAM  
L3           STRUCTURE uploaded  
L4        2 S L3 SSS SAM  
L5        6 S L3 SSS FULL

=> file caplus, medline,

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	192.94	193.15

FILE 'CAPLUS' ENTERED AT 02:36:53 ON 20 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 02:36:53 ON 20 JUN 2008

=> s L5  
L6        20 L5

=> s L6 (P) atorvastatin  
L7        0 L6 (P) ATORVASTATIN

=> and atorvastatin

AND IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s L6 and atorvastatin  
L8        4 L6 AND ATORVASTATIN

=> dup rem L8  
PROCESSING COMPLETED FOR L8  
L9        4 DUP REM L8 (0 DUPLICATES REMOVED)

=> s L9 not pd>20021220

L10

0 L9 NOT PD>20021220

=> d L9 1-4 TI AB IBIB

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Methods of treatment with CETP inhibitors  
AB This invention relates to cholesterol ester transfer protein (CETP) inhibitors, pharmaceutical compns. contg. such inhibitors, and the use of such inhibitors to treat certain disease/conditions optionally in combination with certain therapeutic agents, e.g., HMG CoA reductase inhibitors. Tablets contained active ingredient 0.25-100, microcryst. cellulose 200-650, fumed silica 10-650, and stearic acid 5-15 mg/tablet.

ACCESSION NUMBER: 2007:1088451 CAPLUS

DOCUMENT NUMBER: 147:392438

TITLE: Methods of treatment with CETP inhibitors

INVENTOR(S): Ruggeri, Roger Benjamin

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 58pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007107843	A1	20070927	WO 2007-IB673	20070312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP 2007254466	A	20071004	JP 2007-71833	20070320
PRIORITY APPLN. INFO.:			US 2006-785188P	P 20060322
			US 2006-806841P	P 20060710

OTHER SOURCE(S): MARPAT 147:392438

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors  
AB A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase inhibitor), and a concn.-enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concn. enhancement of the CETP inhibitor when administered to an aq. use environment. The solid amorphous dispersion of torcetrapib and atorvastatin provided a MDC9o for atorvastatin 5.7-fold that provided by cryst. drug.

ACCESSION NUMBER: 2006:1279173 CAPLUS

DOCUMENT NUMBER: 146:50277

TITLE: Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase

INVENTOR(S): inhibitors  
Freisen, Dwayne Thomas; Hancock, Bruno Caspar; Ketner,  
Rodney James; Lyon, David Keith; Nightingale, James  
Alan Schriver; Shanker, Ravi Mysore  
PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
SOURCE: PCT Int. Appl., 43pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006129167	A1	20061207	WO 2006-IB1407	20060522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1893178	A1	20080305	EP 2006-744791	20060522
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2005-686109P	P 20050531
			WO 2006-IB1407	W 20060522
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L9 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN  
TI Controlled release dosage forms containing cholesteryl ester transfer  
protein inhibitors and immediate release of HMG-CoA reductase inhibitors  
AB A dosage form comprises a cholesteryl ester transfer protein inhibitor in  
a solv.-improved form and an HMG-CoA reductase inhibitor, wherein the  
dosage form provides immediate release of the HMG-CoA reductase inhibitor  
and controlled release of the cholesteryl ester transfer protein  
inhibitor. A solv.-improved form of torcetrapib was prepd. by forming a  
solid amorphous dispersion of torcetrapib in hydroxypropyl Me cellulose  
acetate succinate (HPMCAS). The dispersion was prepd. by spray-drying a  
soln. contg. 4.0% torcetrapib, 12.0% HPMCAS-MG (AQUOT-MG), and 84%  
acetone. The soln. was spray-dried by using a pressure spray nozzle.  
ACCESSION NUMBER: 2005:120698 CAPLUS  
DOCUMENT NUMBER: 142:225773  
TITLE: Controlled release dosage forms containing cholesteryl  
ester transfer protein inhibitors and immediate  
release of HMG-CoA reductase inhibitors  
INVENTOR(S): Curatolo, William John; Friesen, Dwayne Thomas;  
Sutton, Steven C.  
PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
SOURCE: PCT Int. Appl., 199 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011634	A1	20050210	WO 2004-IB2457	20040721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004261058	A1	20050210	AU 2004-261058	20040721
CA 2534371	A1	20050210	CA 2004-2534371	20040721
EP 1653926	A1	20060510	EP 2004-744109	20040721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004013363	A	20061010	BR 2004-13363	20040721
CN 1863511	A	20061115	CN 2004-80029003	20040721
JP 2007501217	T	20070125	JP 2006-522426	20040721
US 20050038007	A1	20050217	US 2004-903433	20040730
IN 2006DN00059	A	20070824	IN 2006-DN59	20060103
MX 2006PA01506	A	20060515	MX 2006-PA1506	20060207
NO 2006001072	A	20060504	NO 2006-1072	20060306
PRIORITY APPLN. INFO.:			US 2003-492407P	P 20030804
			WO 2004-IB2457	W 20040721
OTHER SOURCE(S):	MARPAT 142:225773			
REFERENCE COUNT:	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L9 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN  
 TI Compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors  
 AB A compn. comprises (1) a solid amorphous adsorbate comprising a cholesteryl ester transfer protein (CETP) inhibitor and a substrate; and (2) an HMG-CoA reductase inhibitor is disclosed. The solid amorphous adsorbate provides concn. enhancement of the CETP inhibitor relative to a control compn. consisting essentially of the unadsorbed CETP inhibitor alone, resulting in improved bioavailability. A solid amorphous adsorbate was prep'd. from torcetrapib, fumed silica (Cab-O-Sil), and mixed with granules contg. atorvastatin hemicalcium trihydrate, calcium carbonate, microcryst. cellulose, croscarmellose sodium, polysorbate, hydroxypropyl cellulose, and pregelatinized starch, and then pressed into 150 mg compacts. The resulting compacts each contained 32 mg torcetrapib and 3.2 mg atorvastatin trihydrate hemicalcium salt.

ACCESSION NUMBER: 2004:550886 CAPLUS  
 DOCUMENT NUMBER: 141:94364  
 TITLE: Compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors  
 INVENTOR(S): Babcock, Walter Christian; Friesen, Dwayne Thomas; Smithey, Daniel Tod; Shanker, Ravi Mysore  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 168 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056395	A1	20040708	WO 2003-IB6170	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040132771	A1	20040708	US 2003-678145	20031006
CA 2510458	A1	20040708	CA 2003-2510458	20031218
WO 2004056396	A1	20040708	WO 2003-IB6240	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003285677	A1	20040714	AU 2003-285677	20031218
AU 2003285703	A1	20040714	AU 2003-285703	20031218
EP 1578448	A1	20050928	EP 2003-778668	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017520	A	20051116	BR 2003-17520	20031218
JP 2006512361	T	20060413	JP 2004-561920	20031218
MX 2005PA06167	A	20050826	MX 2005-PA6167	20050609
PRIORITY APPLN. INFO.:			US 2002-435328P	P 20021220
			WO 2003-IB6170	W 20031218
			WO 2003-IB6240	W 20031218
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=> d his

(FILE 'HOME' ENTERED AT 02:21:35 ON 20 JUN 2008)

FILE 'REGISTRY' ENTERED AT 02:22:24 ON 20 JUN 2008

E "(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF  
E "(R)-1-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF  
E "(R)-3-((4-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)(3-(1,1,2,2-TETRAF

L1           STRUCTURE UPLOADED  
L2           3 S L1 SSS SAM  
L3           STRUCTURE UPLOADED  
L4           2 S L3 SSS SAM  
L5           6 S L3 SSS FULL

FILE 'CAPLUS, MEDLINE' ENTERED AT 02:36:53 ON 20 JUN 2008

L6           20 S L5  
L7           0 S L6 (P) ATORVASTATIN  
L8           4 S L6 AND ATORVASTATIN  
L9           4 DUP REM L8 (0 DUPLICATES REMOVED)


L10

O S L9 NOT PD>20021220

=> d L1

L1 HAS NO ANSWERS

L1 STR




Structure attributes must be viewed using STN Express query preparation.

=> d L3

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.